Flunarizine
Antivertigo Preparations
- Drug class
- Antivertigo Preparations
- Availability
- See label
- Routes
- Oral
- Markets covered
- 1
- Products on record
- 1
Overview
Flunarizine is an active pharmaceutical ingredient in the Antivertigo Preparations group (N07CA). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| CA Canada | Health Canada | 1 | March 22, 2025 |
CACanada· Health Canada
1 product
Uses
FLUNARIZINE (flunarizine hydrochloride) is indicated for: Prophylaxis of migraine (with and without aura) in patients with frequent and severe attacks, who have not responded satisfactorily to other treatment and/or in whom other therapy has resulted in unacceptable side effects.
FLUNARIZINE is not indicated for the treatment of acute attacks. 1 Pediatrics Pediatrics (< 18 years of age): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of FLUNARIZINE in pediatric patients has not been established.
3 Pediatrics. 2 Geriatrics Geriatrics (> 65 years of age): The safety and efficacy of FLUNARIZINE in the prophylaxis of migraine has not been established in elderly subjects. 3 Pharmacokinetics, Geriatrics.
Sources & citations
- [1]Health Canada (DPD) · 02246082 · revised March 22, 2025
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.